Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism

Affiliations

Free article

Review

Stephen M Stahl. Int J Neuropsychopharmacol. 2007 Oct.

Free article

. 2007 Oct;10(5):575-8.

doi: 10.1017/S1461145707008000. Epub 2007 Aug 6.

¹ Department of Psychiatry, University of California, San Diego, CA, USA. smstahl@neiglobal.com

No abstract available

Comment on

Major depressive disorder, sleep EEG and agomelatine: an open-label study.
Quera Salva MA, Vanier B, Laredo J, Hartley S, Chapotot F, Moulin C, Lofaso F, Guilleminault C. Quera Salva MA, et al. Int J Neuropsychopharmacol. 2007 Oct;10(5):691-6. doi: 10.1017/S1461145707007754. Epub 2007 May 4. Int J Neuropsychopharmacol. 2007. PMID: 17477886 Clinical Trial.
Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.
Olié JP, Kasper S. Olié JP, et al. Int J Neuropsychopharmacol. 2007 Oct;10(5):661-73. doi: 10.1017/S1461145707007766. Epub 2007 May 4. Int J Neuropsychopharmacol. 2007. PMID: 17477888 Clinical Trial.